Fitusiran Delay Dents Sanofi’s Hemophilia Challenge
Company Still Aiming For Universal Therapy
New data show fitusiran’s promise across hemophilia A and B, but a switch to a lower dose prompted by safety concerns will delay its filing until 2024.
New data show fitusiran’s promise across hemophilia A and B, but a switch to a lower dose prompted by safety concerns will delay its filing until 2024.